News

Investor's Business Daily on MSN15d
Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried
Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.
Novartis gets FDA accelerated approval for Vanrafia
Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor ...
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...
Seeking Alpha16d
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA ...
Novartis is uniquely positioned to lead a transformation in kidney care Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring ...
MPR12d
Vanrafia Gets Accelerated Approval for Immunoglobulin A Nephropathy
The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...
The American Journal of Managed Care7d
New Hope for IgA Nephropathy With Atrasentan Approval: Richard Lafayette, MD, FACP
Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...
Business Insider11d
Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are navigating ...
Morningstar11d
CareMed Has Been Selected as a National Specialty Pharmacy Partner for VANRAFIA™ (atrasentan)
NEW HYDE PARK, N.Y., April 07, 2025 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of ...
DIARIO MEDICO.COM3d
Vía libre de la FDA para el segundo medicamento de Novartis en nefropatía por IgA
Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por Novartis en 2023 por 3.200 millones de dólares. 'Vanrafia' está indicado ...